Quality of life after radiotherapy and steroids. A phase III multi-centre randomised controlled trial to assess whether optimal supportive care alone (including dexamathasone) is as effective as optimal supportive care (including dexamethasone) plus whole brain radiotherapy in the treatment of patients with inoperable brain metastases from non-small cell lung cancer.
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Dexamethasone (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms QUARTZ
- 07 Nov 2013 Accrual to date is 88% according to United Kingdom Clinical Research Network record.
- 04 Oct 2013 Accrual to date is 86% according to United Kingdom Clinical Research Network record.
- 03 Oct 2013 Planned End Date changed from 30 Dec 2013 to 31 Aug 2014 as reported by United Kingdom Clinical Research Network record.